Aeglea biotherapeutics, inc. (AGLE)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Revenues:
Grant

-

-

-

-

-

-22

0

2,400

1,510

-

1,261

1,479

-

-

-

-

-

-

-

-

-

Grant

-

-

-

-

-

-

-

-

-

-

-

-

982

-

1,149

1,373

859

1,585

1,073

3,427

0

Operating expenses:
Research and development

14,562

17,566

17,839

14,806

14,389

11,798

8,929

9,122

6,870

5,792

6,239

5,835

4,949

4,742

5,385

4,420

3,596

3,966

3,129

2,736

1,622

General and administrative

4,460

4,343

4,307

3,816

3,268

3,507

3,314

2,926

2,885

2,318

3,020

2,364

2,364

2,048

2,065

2,448

1,830

1,616

1,361

2,123

847

Total operating expenses

19,022

21,909

22,146

18,622

17,657

15,305

12,243

12,048

9,755

8,110

9,259

8,199

7,313

6,790

7,450

6,868

5,426

5,582

4,490

4,859

2,469

Loss from operations

-19,022

-21,909

-22,146

-18,622

-17,657

-15,305

-12,243

-9,670

-8,245

-6,627

-7,998

-6,720

-6,331

-5,543

-6,301

-5,495

-4,567

-3,997

-3,417

-1,432

-2,469

Other income (expense):
Interest income

300

432

585

619

507

427

339

263

143

151

136

100

95

72

72

74

26

11

5

5

1

Other expense, net

-6

-18

-12

-16

-17

-20

-13

-7

-17

-7

-12

-12

-11

-12

-9

-9

-6

-

-1

-

-

Total other income

294

414

573

603

490

407

326

256

126

144

124

88

84

60

63

65

20

10

4

5

1

Net loss

-18,728

-21,495

-21,573

-18,019

-17,167

-14,898

-11,917

-9,414

-8,119

-6,483

-7,874

-6,632

-6,247

-5,483

-6,238

-5,430

-4,547

-3,987

-3,413

-1,427

-2,468

Deemed dividend to convertible preferred stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

228

Net loss per share, basic and diluted

-0.57

-0.65

-0.66

-0.55

-0.59

-0.64

-0.54

-0.46

-0.49

-0.38

-0.48

-0.47

-0.47

5.81

-0.47

-0.46

-7.10

-6.49

-5.57

-2.44

-4.71

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,987

-3,413

-1,427

-2,696

Weighted-average common shares outstanding, basic and diluted

33,097

33,052

32,894

32,840

29,011

24,032

21,986

20,598

16,672

16,622

16,409

14,114

13,365

13,424

13,326

11,776

640

627

612

585

573